P21 556 431

Manufactured by BD

The P21(556,431) is a laboratory equipment product developed by BD. It is a multi-functional device designed for use in various scientific and research applications. The core function of this product is to provide precise and reliable measurement capabilities to support data collection and analysis within laboratory settings. Further details on the intended use or specific features of this equipment are not available.

Automatically generated - may contain errors

Lab products found in correlation

Flag f3165, by Merck Group (1 mentions) Gfp jl 8, by Takara Bio (1 mentions) β actin a2228, by Merck Group (1 mentions) Ha sc 7392, by Santa Cruz Biotechnology (1 mentions) Phospho iκbα 2859, by Cell Signaling Technology (1 mentions) Gapdh 5174, by Cell Signaling Technology (1 mentions) Propidium iodide, by Merck Group (1 mentions) Ixazomib, by Selleck Chemicals (1 mentions) Parp 556494, by BD (1 mentions)

2 protocols using p21 556 431

Western Blotting Assay for Protein Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

These were carried out as described previously [18 (link), 21 (link)]. Western blotting experiments were usually performed 2–3 times, and representative results are presented in figures. The following primary antibodies were used: ATF3 (sc-188X, 1:10,000), MDM2 (N-20, sc-813, 1:1000), p53 (DO-1, sc-126, 1:1000), and HA (sc-7392, 1:2500) from Santa Cruz Biotechnology; PUMA (2–16, 1:1000) from CALBIOCHEM; p21(556,431, 1:1000) from BD Pharmingen; β-actin (A2228, 1:10,000) and FLAG (F3165, 1:5000) from Sigma; and GFP (JL-8, 1:8000) from Clontech.

Li X., Guo M., Cai L., Du T., Liu Y., Ding H.F., Wang H., Zhang J., Chen X, & Yan C. (2019). Competitive ubiquitination activates the tumor suppressor p53. Cell Death and Differentiation, 27(6), 1807-1818.

+ Open protocol

+ Expand

Comprehensive Protein Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used: b-actin-612656, p65–610868, p21–556431, PARP-556494, and p53–554293; (BD Biosciences); phospho-IκBα−2859, IκBα−9247, GAPDH-5174, Survivin-28023, and p27–3688 (Cell Signaling Technology); Lamin B-6216 and c-Myc-40 (Santa Cruz Biotechnology); and polyubiquitin-SIG-39500 (Covance). Propidium iodide (PI) and RNase were purchased from Sigma-Aldrich and ixazomib from Selleck Chemicals.

Ganguly S., Kuravi S., Alleboina S., Mudduluru G., Jensen R.A., McGuirk J.P, & Balusu R. (2018). Targeted Therapy for EBV-Associated B-cell Neoplasms. Molecular cancer research : MCR, 17(4), 839-844.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!